Félix Paula, Stoermann-Chopard Catherine, Martin Pierre-Yves
Service de médecine interne générale, Département de médecine interne, HUG, 1211 Genève 14.
Rev Med Suisse. 2010 Mar 3;6(238):448-52.
Lithium continues to be the standard for acute and maintenance treatment of bipolar mood disorders despite the availability of alternative agents. Lithium has a narrow therapeutic index and can result in considerable toxicity. Acute renal intoxication is well-known but chronic kidney disease should be in each doctor's mind. The main manifestations are nephrogenic diabetes insipidus (NDI) and tubulointerstitial nephritis. For NDI, the potassium sparing diuretic amiloride or a thiazide diuretic can improve polyuria. Lithium-induced ESRD in chronic tubulointerstitial nephritis is not uncommon and more prevalent (> 1% among long-term lithium patients) than previously thought. The risk of renal failure may persist even after lithium discontinuation. Additional kidney manifestations of lithium exposure include renal tubular acidosis and hypercalcemia.
尽管有其他替代药物,但锂仍然是双相情感障碍急性和维持治疗的标准药物。锂的治疗指数较窄,可能导致相当大的毒性。急性肾中毒众所周知,但慢性肾病应引起每位医生的关注。主要表现为肾性尿崩症(NDI)和肾小管间质性肾炎。对于NDI,保钾利尿剂氨氯吡咪或噻嗪类利尿剂可改善多尿症状。锂诱导的慢性肾小管间质性肾炎导致终末期肾病并不罕见,且比以前认为的更普遍(长期服用锂的患者中>1%)。即使停用锂后,肾衰竭的风险可能仍然存在。锂暴露的其他肾脏表现包括肾小管酸中毒和高钙血症。